Ardelyx Reports Second Quarter 2022 Financial Results and Recent Business Highlights

Rhea-AI Summary

Ardelyx reported its Q2 2022 results, highlighting a successful launch of IBSRELA for IBS-C, with net product sales of $1.6 million. The company enjoys strong market visibility, with 41% of surveyed GIs already using IBSRELA. R&D expenses significantly decreased by 62.6% to $9.7 million, while SG&A expenses fell by 6.3% to $18.9 million. The net loss improved to $26.9 million or $0.19 per share, compared to $45.2 million or $0.45 per share in Q2 2021. Additionally, a $20 million financing agreement was secured with HealthCare Royalty Partners.

Positive

• Strong market response to IBSRELA; 41% of surveyed GIs report usage.
• Research and development expenses decreased by 62.6% to $9.7 million.
• Net loss improved significantly to $26.9 million compared to $45.2 million in Q2 2021.
• Secured a $20 million financing agreement, enhancing cash flow.

Negative

• Collaboration revenue decreased to $1.0 million from $1.3 million year-over-year.

Conference call scheduled for 4:30 p.m. Eastern Time today

WALTHAM, Mass., Aug. 4, 2022 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative first-in-class medicines that meet significant unmet medical needs, today reported business updates and financial results for the second quarter ended June 30, 2022.

"The second quarter marks a significant point of transition for Ardelyx as a commercial company," said Mike Raab, president and chief executive officer of Ardelyx. "We are now three months into the launch of IBSRELA^®, for the treatment of IBS-C in adults, and see that the market is responding enthusiastically to this much-needed innovative therapy. We are building strong relationships with the treating community and across GI practices. Our sales and marketing launch efforts are raising visibility and building a foundational demand for IBSRELA. Separately, the FDA assigned a tentative date for the advisory committee to review our NDA for XPHOZAH^® for hyperphosphatemia, and we look forward to the opportunity to highlight the strong data that support XPHOZAH and its potential to make a difference in the lives of patients with chronic kidney disease on dialysis."

Recent Business Highlights and Updates

• Spherix Global Insights, a company that publishes independent, syndicated monthly tracking research, has included IBSRELA (tenapanor) as one of the key launches to follow in the GI space. Three months post-launch, Spherix reports that with respect to those GIs surveyed in its market research, two-thirds are aware of IBSRELA, 41% report use of IBSRELA, and 92% rate IBSRELA as either a substantial or moderate advance over currently available irritable bowel syndrome with constipation (IBS-C) therapies. In addition, those GIs surveyed reported that 31% of their patients may be candidates for treatment. Among those who have not yet used IBSRELA, 57% expect to use it within three months and an additional 21% expect to use within six months. 
• The American Gastroenterological Association (AGA) announced their updated Clinical Practice Guideline on the "Pharmacological Management of Irritable Bowel Syndrome with Constipation." The updated guideline includes IBSRELA in their IBS-C treatment recommendations. 
• The company presented multiple posters at the Digestive Disease Week Conference (DDW 2022) in San Diego, CA on May 21-24, 2022, which included long-term data demonstrating the impact of IBSRELA on abdominal pain and other abdominal symptoms; effect of IBSRELA on treatment satisfaction, degree of relief, and quality of life; and early onset of action in treating symptoms of irritable bowel syndrome with constipation.  
• On June 21, 2022, the company announced that the U.S. Food and Drug Administration (FDA) informed the company that a meeting of the Cardiovascular and Renal Drugs Advisory Committee (Advisory Committee) is tentatively scheduled for November 16, 2022. As part of the Formal Dispute Resolution Request (FDRR), the Advisory Committee is being convened at the request of FDA's Office of New Drugs (OND) in order to provide input regarding the clinical meaningfulness of the phosphate lowering effect observed in the company's Phase 3 clinical program for XPHOZAH (tenapanor) for the control of serum phosphorus in adult patients with chronic kidney disease (CKD) on dialysis.
• On June 30, 2022, the company announced a $20 million financing agreement with HealthCare Royalty Partners (HealthCare Royalty) based on the sale of its future royalties and sales milestones from Kyowa Kirin Co., Ltd (Kyowa Kirin), its collaboration partner in Japan, for the commercialization of tenapanor for hyperphosphatemia. Under the agreement, the company received from HealthCare Royalty a $10 million upfront payment and is entitled to an additional $5 million following Kyowa Kirin's receipt of regulatory approval to market tenapanor for hyperphosphatemia in Japan, and $5 million in the event net sales in Japan exceed a certain target level in 2025. In return, HealthCare Royalty will receive the royalty payments and commercial sales milestones that the company may earn under the license agreement with Kyowa Kirin.

Second Quarter 2022 Financial Results

• Cash Position: As of June 30, 2022, the company had total cash, cash equivalents and investments of $81.0 million, as compared to total cash, cash equivalents and investments of $116.7 million as of December 31, 2021.
• Product Sales: Net product sales for IBSRELA were $1.6 million during the quarter ended June 30, 2022.
• Collaboration Revenue: The company generated $1.0 million in collaboration revenue for the quarter ended June 30, 2022, as compared to $1.3 million for the quarter ended June 30, 2021. The decrease in collaboration revenue was primarily the result of the recognition of the previously received upfront payment from the 2019 research and collaboration agreement between the company and Kyowa Kirin that was fully earned and recognized as revenue as of December 31, 2021. The decrease in collaboration revenue was partially offset by product supply revenue related to the manufacturing and supply of tenapanor and other materials for Kyowa Kirin pursuant to the 2017 license agreement between the company and Kyowa Kirin.
• R&D Expenses: Research and development expenses were $9.7 million for the quarter ended June 30, 2022, a decrease of $16.3 million, or 62.6%, compared to $26.0 million for the quarter ended June 30, 2021. Research and development expenses included non-cash stock compensation expense of approximately $1.0 million and $1.1 million in the quarters ended June 30, 2022, and June 30, 2021, respectively. The decrease in R&D expenses is primarily the result of lower clinical study costs from the OPTIMIZE study, lower tenapanor manufacturing expenses due to the company's capitalization of costs associated with the production of IBSRELA to inventory, and lower expenses for research following the elimination of the company's research function in the fourth quarter of 2021.
• SG&A Expenses: Selling, general and administrative expenses were $18.9 million for the quarter ended June 30, 2022, a decrease of $1.3 million, or 6.3%, compared to $20.1 million for the quarter ended June 30, 2021. Selling, general and administrative expenses included non-cash stock compensation expense of approximately $2.2 million and $2.1 million in the quarters ended June 30, 2022, and June 30, 2021, respectively. The decrease in selling, general and administrative expenses was primarily due to the timing of costs associated with preparing for and carrying out the commercial launch of IBSRELA.
• Net Loss: Net loss for the quarter ended June 30, 2022 was $26.9 million, or $0.19 per share, compared to $45.2 million, or $0.45 per share, for the quarter ended June 30, 2021.

Conference Call Details

The company will host a conference call today, August 4, 2022, at 4:30 p.m. ET to review its financial results and provide a business overview. To participate in the conference call via telephone, please register using this online form. Live audio of the conference call will be simultaneously webcast and will be available under the Investors section of the company's website at www.ardelyx.com. The webcast will be archived and available for replay for 30 days following the call.

IMPORTANT SAFETY INFORMATION

WARNING: RISK OF SERIOUS DEHYDRATION IN PEDIATRIC PATIENTS
IBSRELA is contraindicated in patients less than 6 years of age; in nonclinical studies in young juvenile rats administration of tenapanor caused deaths presumed to be due to dehydration. Avoid use of IBSRELA in patients 6 years to less than 12 years of age. The safety and effectiveness of IBSRELA have not been established in patients less than 18 years of age.

CONTRAINDICATIONS

• IBSRELA is contraindicated in patients less than 6 years of age due to the risk of serious dehydration.
• IBSRELA is contraindicated in patients with known or suspected mechanical gastrointestinal obstruction.

WARNINGS AND PRECAUTIONS

Risk of Serious Dehydration in Pediatric Patients

• IBSRELA is contraindicated in patients below 6 years of age. The safety and effectiveness of IBSRELA in patients less than 18 years of age have not been established. In young juvenile rats (less than 1 week old; approximate human age equivalent of less than 2 years of age), decreased body weight and deaths occurred, presumed to be due to dehydration, following oral administration of tenapanor. There are no data available in older juvenile rats (human age equivalent 2 years to less than 12 years).
• Avoid the use of IBSRELA in patients 6 years to less than 12 years of age. Although there are no data in older juvenile rats, given the deaths in younger rats and the lack of clinical safety and efficacy data in pediatric patients, avoid the use of IBSRELA in patients 6 years to less than 12 years of age.

Diarrhea

Diarrhea was the most common adverse reaction in two randomized, double-blind, placebo-controlled trials of IBS-C. Severe diarrhea was reported in 2.5% of IBSRELA-treated patients.  If severe diarrhea occurs, suspend dosing and rehydrate patient.

MOST COMMON ADVERSE REACTIONS

The most common adverse reactions in IBSRELA-treated patients (incidence ≥2% and greater than placebo) were: diarrhea (16% vs 4% placebo), abdominal distension (3% vs <1%), flatulence (3% vs 1%) and dizziness (2% vs <1%).

INDICATION

IBSRELA (tenapanor) is indicated for the treatment of Irritable Bowel Syndrome with Constipation (IBS-C) in adults.

Please see full Prescribing Information, including Boxed Warning, for additional risk information.

About Ardelyx, Inc.

Ardelyx was founded with a mission to discover, develop and commercialize innovative first-in-class medicines that meet significant unmet medical needs. Ardelyx's first approved product, IBSRELA^® (tenapanor) is available in the United States and Canada. Ardelyx is developing XPHOZAH^® (tenapanor), a novel product candidate to control serum phosphorus in adult patients with CKD on dialysis, which has completed three successful Phase 3 trials. Ardelyx has a Phase 2 potassium secretagogue program, RDX013, for the potential treatment of elevated serum potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart disease and an early-stage program in metabolic acidosis, a serious electrolyte disorder in patients with CKD. Ardelyx has established agreements with Kyowa Kirin in Japan, Fosun Pharma in China and Knight Therapeutics in Canada for the development and commercialization of tenapanor in their respective territories.

Forward Looking Statements

To the extent that statements contained in this press release are not descriptions of historical facts regarding Ardelyx, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor of the Private Securities Reform Act of 1995, including Ardelyx's current expectation regarding the timing of the Advisory Committee meeting to be convened to provide input regarding the clinical meaningfulness of the phosphate lowering effect observed in the Phase 3 clinical program for XPHOZAH, the potential receipt by Ardelyx of additional payments under the royalty financing agreement with HealthCare Royalty, and the potential for additional GIs to begin use of IBSRELA in the next three to six months as reported by the Spherix report. Such forward-looking statements involve substantial risks and uncertainties that could cause Ardelyx's future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, uncertainties associated with the FDA's regulatory process, uncertainties in the drug development and regulatory processes in Japan and uncertainties associated with the commercialization of drugs. Ardelyx undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Ardelyx's business in general, please refer to Ardelyx's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 4, 2022, and its future current and periodic reports to be filed with the Securities and Exchange Commission.

Ardelyx, Inc.
Condensed Balance Sheets
(In thousands)
	June 30, 2022		December 31, 2021
	(Unaudited)		(1)
Assets
Cash and cash equivalents	$                   53,408		$                   72,428
Investments	27,604		44,261
Accounts receivable	5,623		502
Inventory	4,529		—
Property and equipment, net	1,541		2,362
Right-of-use assets	11,054		12,752
Prepaid commercial manufacturing	17,793		9,406
Prepaid and other assets	10,058		8,202
Total assets	$                 131,610		$                 149,913
Liabilities and stockholders' equity
Accounts payable	$                     4,294		$                     4,277
Accrued compensation and benefits	6,405		5,422
Current portion of operating lease liability	3,691		3,492
Current portion of long-term debt	26,373		32,264
Deferred revenue	12,421		4,727
Accrued expenses and other liabilities	7,936		7,366
Operating lease liability, net of current portion	7,857		9,748
Deferred royalty obligation	9,591		—
Stockholders' equity	53,042		82,617
Total liabilities and stockholders' equity	$                 131,610		$                 149,913

(1)	Derived from the audited financial statements included in the Company's Annual Report on Form 10-K for the year ended December 31, 2021.

 

Ardelyx, Inc.
Condensed Statements of Operations
(Unaudited)
(In thousands, except share and per share amounts)
	Three Months Ended June 30,				Six Months Ended June 30,
	2022		2021		2022		2021
Revenues:
Product sales, net	$                 1,564		$                     —		$              2,014		$                   —
Product supply revenue	952		—		966		126
Licensing revenue	10		3		14		5,005
Collaborative development revenue	—		1,310		—		2,764
Total revenues	2,526		1,313		2,994		7,895
Operating expenses:
Cost of revenue	138		—		223		1,000
Research and development	9,741		26,021		18,592		46,477
Selling, general and administrative	18,862		20,124		38,201		37,255
Total operating expenses	28,741		46,145		57,016		84,732
Loss from operations	(26,215)		(44,832)		(54,022)		(76,837)
Interest expense	(787)		(1,202)		(1,533)		(2,302)
Other income, net	70		847		554		798
Loss before provision for income taxes	(26,932)		(45,187)		(55,001)		(78,341)
Provision for income taxes	6		2		8		3
Net loss	$            (26,938)		$           (45,189)		$         (55,009)		$         (78,344)
Net loss per common share, basic and diluted	$                (0.19)		$               (0.45)		$             (0.40)		$             (0.79)
Shares used in computing net loss per share - basic and diluted	145,544,372		100,040,083		138,279,945		98,617,564

 

 

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/ardelyx-reports-second-quarter-2022-financial-results-and-recent-business-highlights-301600379.html

SOURCE Ardelyx

FAQ

What were Ardelyx's Q2 2022 financial results?

Ardelyx reported a net loss of $26.9 million or $0.19 per share, with net product sales of $1.6 million for IBSRELA.

What is the status of IBSRELA in the market?

Three months post-launch, 41% of surveyed gastroenterologists are using IBSRELA, and it has garnered positive feedback.

What financing agreement did Ardelyx secure recently?

Ardelyx secured a $20 million financing agreement with HealthCare Royalty Partners related to tenapanor.

What are Ardelyx's plans for XPHOZAH?

Ardelyx anticipates an FDA advisory committee meeting for XPHOZAH on November 16, 2022, focusing on its phosphate-lowering effect.